The provided information details several pharmaceutical and healthcare companies along with their forward dividend yields and implied upside from the closing prices on October 9. Here's a summary of the key points:

1. Roche Holding AG (RHHBY):

   • Forward Dividend Yield: 3.8%

   • Implied Upside: 61.9%

   • Roche is a Swiss pharmaceutical and diagnostics company known for products like Avastin, Herceptin, and Rituxan. Despite concerns about the approval of the oncology drug candidate tiragolumab, analysts remain bullish on Roche's portfolio and pipeline.

2. AstraZeneca PLC (AZN):

   • Forward Dividend Yield: 2.2%

   • Implied Upside: 16.3%

   • AstraZeneca is one of the largest pharmaceutical companies globally, with a strong pipeline. Despite potential risks to Tagrisso's sales, analysts believe in AstraZeneca's long-term prospects.

3. Pfizer Inc. (PFE):

   • Forward Dividend Yield: 4.9%

   • Implied Upside: 44.6%

   • Pfizer is one of the world's largest pharmaceutical companies, well-known for its COVID-19 vaccines and other treatments. Analysts suggest steady growth through 2028, and they remain positive about its future.

4. Sanofi SA (SNY):

   • Forward Dividend Yield: 3.5%

   • Implied Upside: 12.9%

   • Sanofi specializes in atopic allergic disorders, oncology, and rare diseases. Strong growth in immunology drug Dupixent sales is seen as a positive factor for the company.

5. Bristol-Myers Squibb Co. (BMY):

   • Forward Dividend Yield: 4%

   • Implied Upside: 16.6%

   • Bristol-Myers Squibb is a biopharmaceutical company with a focus on oncology, immunology, and cardiovascular therapeutics. Its pipeline drugs are expected to offset patent losses for key drugs.

6. Gilead Sciences Inc. (GILD):

   • Forward Dividend Yield: 4%

   • Implied Upside: 29.2%

   • Gilead Sciences develops treatments for HIV/AIDS, hepatitis C, and other conditions. Analysts are impressed by the company's potential in the HIV and oncology markets.

7. GSK PLC (GSK):

   • Forward Dividend Yield: 3.8%

   • Implied Upside: 45.6%

   • GSK is one of the largest pharmaceutical companies with a focus on asthma, bronchospasm, and HIV treatments. Longer-duration HIV treatments are expected to mitigate patent expirations.

These figures provide insights into the dividend yields and potential for stock price appreciation for these pharmaceutical companies. It's essential to conduct further research and consider your investment goals and risk tolerance before making investment decisions.

[email protected]